Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8121605 | 1.00 | RAB9A (0.44) | RAB9AMAPTPOLBFAAHNPC1 | |
| SCHEMBL13320913 | 0.85 | MAPT (0.46) | RAB9AMAPTPOLBFAAHNPC1 | |
| SCHEMBL17492229 | 0.84 | AAK1 (0.54) | ACEAAK1 | |
| SCHEMBL17492226 | 0.84 | AAK1 (0.54) | ACEAAK1 | |
| SCHEMBL13376991 | 0.80 | ACE (0.40) | FAAHSMN1; SMN2ACEAAK1 | |
| SCHEMBL29992146 | 0.77 | PPARG (0.44) | LMNASMN1; SMN2 | |
| SCHEMBL17492065 | 0.76 | AAK1 (0.53) | FAAHAAK1 | |
| SCHEMBL17492068 | 0.76 | AAK1 (0.53) | FAAHAAK1 | |
| SCHEMBL13197626 | 0.74 | MEN1 (0.44) | RAB9AMAPTPOLBLMNASMN1; SMN2 | |
| SCHEMBL13197618 | 0.74 | MEN1 (0.44) | RAB9AMAPTPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217009-A1 | Process for Preparing Chroman Derivatives | BIAL - PORTELA & CA, S.A. (PT) | 2010-08-26 | — | — | US | disclosed |
| WO-2008143540-A1 | PROCESS FOR PREPARING CHROMAN DERIVATIVES | BIAL-PORTELA & CA, S.A. (PT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217009-A1 | Process for Preparing Chroman Derivatives | CYP4A22, CYP2F1, CYP2C19 | RAB9A 1087/4885MAPT 4853/4885POLB 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.